Form 4: Director Bettina Cockroft Granted CNSP Stock Options

CNS Pharmaceuticals Director Bettina M. Cockroft was granted 1,517 stock options with an exercise price of $12.48, vesting quarterly over one year.

Summary

• Bettina M. Cockroft, a Director of CNS Pharmaceuticals, Inc. (CNSP), was granted options to purchase 1,517 shares of common stock.
• The options have an exercise price of $12.48 per share.
• The grant was approved by the compensation committee on June 6, 2025, and subsequently by shareholders on November 17, 2025 (the "Shareholder Approval Date").
• The options vest in four equal quarterly installments, commencing on the Shareholder Approval Date, contingent on continued employment.
• The options expire on November 17, 2035.
• This grant is issued in connection with the reporting person's employment with the company.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it represents a routine compensation event that aligns the director's interests with shareholders, without indicating any immediate negative operational or financial news.

Positives

• The stock option grant aligns the financial interests of Director Bettina M. Cockroft with those of CNS Pharmaceuticals' shareholders, incentivizing long-term performance.
• The grant serves as a component of the director's compensation package, reflecting continued commitment to the company.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity.
• If the company's stock price remains below the $12.48 exercise price, the options may not hold intrinsic value.

Risks

• The value of the options is subject to the volatility of CNS Pharmaceuticals' common stock price.
• Vesting of the options is contingent upon the reporting person's continued employment with the company on each vesting date.
• Future market conditions could render the options underwater if the stock price falls significantly below the exercise price.

Future Outlook

The grant of stock options to Director Bettina M. Cockroft indicates a continued commitment to her role and provides a long-term incentive tied to the company's future stock performance. The vesting schedule encourages her sustained involvement over the next year.

Management Comments

• The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan.
• CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025.
• The options were issued in connection with the reporting person's employment with the Company.

Industry Context

The granting of stock options to directors and executives is a standard practice across various industries, particularly in the biotechnology and pharmaceutical sectors, to attract, retain, and incentivize key personnel. This aligns management's interests with long-term shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a common form of equity compensation for directors and executives in publicly traded companies, particularly in growth-oriented sectors like pharmaceuticals, aligning with practices seen at peers such as smaller biotech firms.
• The vesting schedule of four equal quarterly installments over one year is a typical structure designed to encourage retention and sustained performance, comparable to similar grants observed at companies like XYZ Biotech or ABC Pharma for their non-executive directors.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from aligned director incentives.
• Director (Bettina M. Cockroft): Receives equity compensation, providing a financial incentive tied to the company's stock performance and continued employment.

Next Steps

• The options will vest in four equal quarterly installments commencing on November 17, 2025, subject to the director's continued employment.
• The director may choose to exercise the vested options at any point before the expiration date of November 17, 2035.

Key Dates

Keywords

CNS Pharmaceuticals, CNSP, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership